The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
08-Aug-11
$11.0 billion
Target:
Coal and Allied Industries Limited
Acquiror:
Rio Tinto Limited / Mitsubishi Corporation
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
01-Dec-10
$NA
Target:
Planar Solutions, LLC
Acquiror:
FUJIFILM Corporation
Advised Wacker Chemie AG on the sale of Wacker Chemical Corporation’s 50% equity stake in Planar Solutions LLC, a dedicated CMP slurry manufacturer, to its JV partner, FUJIFILM Corporation
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
01-Jun-10
$109 million
Target:
AT&T Japan (an AT&T Inc. company)
Acquiror:
Internet Initiative Japan
Advised AT&T Inc., a premier communications holding company, on its sale of the domestic network outsourcing business of AT&T Japan, its Japanese enterprise unit, to Internet Initiative Japan, one of Japan's leading Internet-access and comprehensive network solutions providers
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
03-May-07
$8.5 billion
Target:
IPSCO Inc.
Acquiror:
SSAB Svenskt Stål AB
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons